' '
Deutsch | English    

Forschungsdatenbank PMU-SQQUID

Idarucizumab in major trauma patients: a single centre real life experience.
Oberladstatter, D; Voelckel, W; Bruckbauer, M; Zipperle, J; Grottke, O; Ziegler, B; Schochl, H
EUR J TRAUMA EMERG S. 2021; 47(2): 589-595.
Originalarbeiten (Zeitschrift)


Ziegler Bernhard


Trauma care providers are facing an increasing number of elderly patients on direct oral anticoagulants prior to injury. For dabigatran etexilate (DAB), the specific antagonist idarucizumab (IDA) has been approved since 2015 as a reversal agent. However, only limited data regarding the use of IDA in trauma patients are available.
We performed a retrospective analysis of trauma patients under DAB for whom IDA administration was deemed necessary to reverse DAB"s antithrombotic effect.
A total of 15 (9 male) patients were treated with IDA during the study period. The mean age was 81 ± 10 years. Intracranial haemorrhage (n = 7) and long bone fractures (n = 5) were the most common types of injury. Three patients were diagnosed as polytrauma. In all but one patient, atrial fibrillation was the indication for DAB intake. The median dose of IDA was 2.5 g (IQR 2.5-5). IDA administration decreased DAB plasma levels from 112.4 (IQR 73.4-123.4) to 5 (IQR 4-12) ng/mL (p = 0.031), thrombin time from 114.8 ± 48.3 to 16.2 ± 0.5 s (p < 0.0001) and activated partial thromboplastin time form 45.4 ± 11.3 to 34.2 ± 7.0 s (p = 0.0025). No thromboembolic events or side effects attributed to IDA were observed. All patients survived until hospital discharge.
In trauma patients under DAB prior to injury, IDA decreased DAB plasma levels and normalized coagulation parameters. IDA appears to be safe, and no serious side effects were observed in this small cohort of patients.

Find related publications in this database (Keywords)